1. Home
  2. BNTC vs RECT Comparison

BNTC vs RECT Comparison

Compare BNTC & RECT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNTC
  • RECT
  • Stock Information
  • Founded
  • BNTC 1995
  • RECT 1997
  • Country
  • BNTC United States
  • RECT Singapore
  • Employees
  • BNTC N/A
  • RECT N/A
  • Industry
  • BNTC Biotechnology: Pharmaceutical Preparations
  • RECT
  • Sector
  • BNTC Health Care
  • RECT
  • Exchange
  • BNTC Nasdaq
  • RECT Nasdaq
  • Market Cap
  • BNTC 88.1M
  • RECT 101.0M
  • IPO Year
  • BNTC N/A
  • RECT 2024
  • Fundamental
  • Price
  • BNTC $10.30
  • RECT $6.72
  • Analyst Decision
  • BNTC Buy
  • RECT
  • Analyst Count
  • BNTC 6
  • RECT 0
  • Target Price
  • BNTC $23.83
  • RECT N/A
  • AVG Volume (30 Days)
  • BNTC 82.8K
  • RECT 25.3K
  • Earning Date
  • BNTC 02-11-2025
  • RECT 03-03-2025
  • Dividend Yield
  • BNTC N/A
  • RECT N/A
  • EPS Growth
  • BNTC N/A
  • RECT N/A
  • EPS
  • BNTC N/A
  • RECT 0.20
  • Revenue
  • BNTC N/A
  • RECT $30,673,388.00
  • Revenue This Year
  • BNTC N/A
  • RECT N/A
  • Revenue Next Year
  • BNTC N/A
  • RECT N/A
  • P/E Ratio
  • BNTC N/A
  • RECT $33.75
  • Revenue Growth
  • BNTC N/A
  • RECT 9.86
  • 52 Week Low
  • BNTC $2.70
  • RECT $2.70
  • 52 Week High
  • BNTC $13.29
  • RECT $7.68
  • Technical
  • Relative Strength Index (RSI)
  • BNTC 41.00
  • RECT N/A
  • Support Level
  • BNTC $10.20
  • RECT N/A
  • Resistance Level
  • BNTC $11.39
  • RECT N/A
  • Average True Range (ATR)
  • BNTC 0.87
  • RECT 0.00
  • MACD
  • BNTC -0.19
  • RECT 0.00
  • Stochastic Oscillator
  • BNTC 3.58
  • RECT 0.00

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

About RECT Rectitude Holdings Ltd Ordinary Shares

Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks.

Share on Social Networks: